Migrastatics - Anti-metastatic and Anti-invasion Drugs: Promises and Challenges

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F17%3A43913321" target="_blank" >RIV/00216208:11120/17:43913321 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/17:10364793 RIV/00064165:_____/17:10364793

Výsledek na webu

<a href="https://doi.org/10.1016/j.trecan.2017.04.008" target="_blank" >https://doi.org/10.1016/j.trecan.2017.04.008</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.trecan.2017.04.008" target="_blank" >10.1016/j.trecan.2017.04.008</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Migrastatics - Anti-metastatic and Anti-invasion Drugs: Promises and Challenges

Popis výsledku v původním jazyce

In solid cancers, invasion and metastasis account for more than 90% of mortality. However, in the current armory of anticancer therapies, a specific category of anti-invasion and antimetastatic drugs is missing. Here, we coin the term &apos;migrastatics&apos; for drugs interfering with all modes of cancer cell invasion and metastasis, to distinguish this class from conventional cytostatic drugs, which are mainly directed against cell proliferation. We define actin polymerization and contractility as target mechanisms for migrastatics, and review candidate migrastatic drugs. Critical assessment of these antimetastatic agents is warranted, because they may define new options for the treatment of solid cancers. Local invasion and metastasis, rather than clonal proliferation, are the dominant features of solid cancer. However, a specific category of anti-invasion and antimetastatic drugs is missing for treatment of solid cancer. We propose the term &apos;migrastatics&apos; for drugs interfering with all modes of cancer cell invasiveness and, consequently, with their ability to metastasize (e.g., inhibiting not only local invasion, but also extravasation and metastatic colonization).In solid cancer, drug resistance is the main cause of treatment failure, and is attributed to mutations of the target. Since targeting the cause, although academically desirable, may be futile, a pragmatic and near-term option is to move downstream, to common denominators of cell migration and/or invasion, such as actin polymerization and actomyosin-mediated contractility.

Název v anglickém jazyce

Migrastatics - Anti-metastatic and Anti-invasion Drugs: Promises and Challenges

Popis výsledku anglicky

In solid cancers, invasion and metastasis account for more than 90% of mortality. However, in the current armory of anticancer therapies, a specific category of anti-invasion and antimetastatic drugs is missing. Here, we coin the term &apos;migrastatics&apos; for drugs interfering with all modes of cancer cell invasion and metastasis, to distinguish this class from conventional cytostatic drugs, which are mainly directed against cell proliferation. We define actin polymerization and contractility as target mechanisms for migrastatics, and review candidate migrastatic drugs. Critical assessment of these antimetastatic agents is warranted, because they may define new options for the treatment of solid cancers. Local invasion and metastasis, rather than clonal proliferation, are the dominant features of solid cancer. However, a specific category of anti-invasion and antimetastatic drugs is missing for treatment of solid cancer. We propose the term &apos;migrastatics&apos; for drugs interfering with all modes of cancer cell invasiveness and, consequently, with their ability to metastasize (e.g., inhibiting not only local invasion, but also extravasation and metastatic colonization).In solid cancer, drug resistance is the main cause of treatment failure, and is attributed to mutations of the target. Since targeting the cause, although academically desirable, may be futile, a pragmatic and near-term option is to move downstream, to common denominators of cell migration and/or invasion, such as actin polymerization and actomyosin-mediated contractility.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Trends in Cancer

ISSN

2405-8025

e-ISSN

—

Svazek periodika

3

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

16

Strana od-do

391-406

Kód UT WoS článku

000425969500002

EID výsledku v databázi Scopus

2-s2.0-85019948751